SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
  • 2
    Lampert IA, Wotherspoon A, Van Noorden S, Hasserjian RP. High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. Hum Pathol. 1999; 30: 648-654.
  • 3
    Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005; 115: 755-764.
  • 4
    Obermann EC, Went P, Tzankov A, et al. Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. J Clin Pathol. 2007; 60: 794-797.
  • 5
    Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma. 2006; 47: 827-836.
  • 6
    Tsimberidou AM, Keating MJ. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol. 2006; 33: 250-256.
  • 7
    Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology. 2004; 9: 279-286.
  • 8
    Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter's transformation. Am J Hematol. 1999; 60: 99-104.
  • 9
    Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia. Cancer. 2006; 107: 1294-1302.
  • 10
    Lu ZX, Ma XQ, Yang LF, et al. DNAzymes targeted to EBV-encoded latent membrane protein induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett. 2005; 265: 226-238.
  • 11
    D'Souza BN, Edelstein LC, Pegman PM, et al. Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol. 2004; 78: 1800-1816.
  • 12
    Schlette E, Bueso-Ramos C, Giles F, et al. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol. 2001; 115: 571-581.
  • 13
    Boom R, Sol CJA, Saliman MMM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990; 28: 495-503.
  • 14
    Brink AA, Vervoort MB, Middeldrop JM, Meijer CJ, Van den Brule AJ. Nucleic acid sequence-based amplification of spliced and unspliced Epstein-Barr latent transcripts. J Clin Microbiol. 1998; 36: 3164.
  • 15
    Greijer AE, Dekkers CA, Middeldorp JM. Human cytomegalovirus virions differentially incorporate viral and host cell RNA during the assembly process. J Virol. 2000; 74: 9078-9082.
  • 16
    Patterson SS, Casper ET, Garcia-Rubio I, Smith MC, Paul JH. Increased precision of microbial RNA quantification using NASBA with an internal control. J Microbiol Methods. 2005; 60: 343-352.
  • 17
    Dixon EP, King LM, Adams MD, et al. Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of EPV E6/E7 mRNA using the PreTectt HPVpProofer assay. J Virol Methods. 2008; 154: 220-222.
  • 18
    Deiman B, van Aarle P, Sillekens P. Characteristics and applications of nucleic acid sequence based amplification. Mol Biotechnol. 2007; 20: 163-179.
  • 19
    Kirkman TW. Statistics to use. Monograph online, 1996. Available at: http://www.physics.csbsju.edu/stats/ Accessed March 18, 2009.
  • 20
    Wu TC, Mann RB, Epstein JI, et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol. 1991; 138: 1461-1469.
  • 21
    Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 1999; 59( 7 suppl): 1693s-1700s.
  • 22
    Bogner C, Schneller F, Hipp S, et al. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol. 2003; 31: 218-225.
  • 23
    Inamdar KV, O'Brien S, Sen S, et al. Aurora: a kinase nuclear expression in chronic lymphocytic leukemia. Mod Pathol. 2008; 21: 1428-1435.
  • 24
    Blay JY, Voorzanger N, Favrot M, Burdin N, Rousset F, Banchereau J. Presence of Epstein-Barr virus viral interleukin 10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large-cell non-Hodgkin's lymphomas. Blood. 1995; 86: 4702-4704.
  • 25
    Fayad L, Keating MJ, Reuben JM, et al. Interleukin 6 and interleukin 10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001; 97: 256-263.
  • 26
    Lazzarino M, Orlandi E, Baldanti F, et al. The immunosuppression and potential of rEBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol. 199; 107: 877-882.
  • 27
    Laytragoon-Lewin N, Chen F, Avila-Carino J, et al. Epstein Barr virus (EBV)-carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPs but not EBNA2 in vivo. Int J Cancer. 1995; 63: 486-490.
  • 28
    Laytragoon-Lewin N, Chen F, Castro J, Avila-Carino J, Lewin F. Cytokines and Epstein Barr virus (EBV) genes expression in blood chronic lymphocytic leukemia (CLL) cells and their immortalized CLL cell lines. Anticancer Res. 2003; 23: 4017-4022.